Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;83(2):677-679.
doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.

The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Marilyn T Wan  1 , Daniel B Shin  1 , Kevin L Winthrop  2 , Joel M Gelfand  3
Affiliations

The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Marilyn T Wan et al. J Am Acad Dermatol. 2020 Aug.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Meta-estimate of respiratory tract infections (includes “upper respiratory tract infections,” “nasopharyngitis,” “rhinorrhea,” “influenza,” “oropharyngitis,” “pharyngitis,” and “pharyngolaryngeal pain”) from prescribing information adverse events tables. Doses used in this meta-estimate: secukinumab, 300 mg; brodalumab, 210 mg; and ixekizumab, 80 mg every 2 weeks, because these doses are indicated for moderate to severe psoriasis. The size of the square corresponds to the relative weight assigned in the pooled analysis, and the horizontal lines indicate the confidence interval (CI). The diamond denotes the overall effect size, and the lateral tips of the diamond indicate the associated CI. REML, Restricted maximum likelihood.
Fig 2
Fig 2
Meta-estimate of respiratory tract infections (includes “upper respiratory tract infections,” “viral respiratory tract infections,” “influenza,” “influenza-like illness,” “sinusitis,” “pharyngitis,” “bronchitis,” “cough,” “nasopharyngitis,” “oropharyngeal pain,” and “pneumonia”) from clinicaltrials.gov in the phase 3 randomized control trials that were submitted for United States Food and Drug Administration approval. Doses used in this meta-estimate: secukinumab, 300 mg; brodalumab, 210 mg; and ixekizumab, 80 mg every 2 weeks, because these doses are indicated for moderate to severe psoriasis. The size of the square corresponds to the relative weight assigned in the pooled analysis, and the horizontal lines indicate the confidence interval (CI). The diamond denotes the overall effect size, and the lateral tips of the diamond indicate the associated CI. REML, Restricted maximum likelihood.
See this image and copyright information in PMC

Comment in

References

    1. Menter A., Strober B.E., Kaplan D.H., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. - PubMed
    1. Lebwohl M., Rivera-Oyola R., Murrell D.F. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217–1218. - PMC - PubMed
    1. Schett G., Sticherling M., Neurath M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272. - PMC - PubMed
    1. Das S., Khader S. Yin and yang of interleukin-17 in host immunity to infection. F1000Res. 2017;6:741. - PMC - PubMed
    1. American Academy of Dermatology Association Guidance on the use of immunosuppressive agents. https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics Available at:

Publication types

MeSH terms